{"groups":[{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nNetupitant and Palonosetron\n\nDexamethasone","id":"FG000","title":"Netupitant and Palonosetron Plus Dexamethasone"},{"description":"Oral aprepitant hard capsule 125 mg (on Day 1) + 80 mg daily (for the following two days) and oral palonosetron soft capsule 0.50 mg (on Day 1) given with oral dexamethasone at each scheduled chemotherapy cycle.\n\nAprepitant\n\nPalonosetron\n\nDexamethasone","id":"FG001","title":"Aprepitant and Palonosetron Plus Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"comment":"number of randomised patients","groupId":"FG000","numSubjects":"309"},{"comment":"number of randomised patients","groupId":"FG001","numSubjects":"104"}],"type":"STARTED"},{"achievements":[{"comment":"number of patients completing planned/unplanned chemotherapy cycles","groupId":"FG000","numSubjects":"181"},{"comment":"number of patients completing planned/unplanned chemotherapy cycles","groupId":"FG001","numSubjects":"55"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"128"},{"groupId":"FG001","numSubjects":"49"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 413 patients were randomized (ITT population), 412 patients received study drugs i.e.netupitant/palonosetron combination or aprepitant/palonosetron regimen, both with dexamethasone (safety population)"}